Periodic Reporting for period 1 - iGOLDD (Commercialising MR-HIFU: an Image-Guided Local Drug-Delivery Platform)
Reporting period: 2016-10-01 to 2018-03-31
Temperature sensitive liposome-encapsulated radiosensitizers in combination with local hyperthermia are expected to overcome the limitations on optimal – clinically relevant – use of local delivery of radiosensitizer agents, because of the intravascular “burst” release upon hyperthermia. Our translational research team has come together around the notion that the image-guided drug delivery platform can be commercially developed for cancer patients to benefit from improved pharmacodynamic and pharmacokinetic properties of radiosensitizer delivery. A co-dvelopment proposition strategy was prepared to provide a route-to-market of the developed local drug delivery platform. Based on this strategy, preliminary agreement has been reached with key European commercial partners to co-develop the technology into a commercial application.